Light-controlled oxygen production and collection for sustainable photodynamic therapy in tumor hypoxia

Wang, Haoran; Guo, Yunfei; Wang, Chao; Jiang, Xing; Liu, Honghui; Yuan, Ahu; Yan, Jing; Hu, Yiqiao; Wu, Jinhui

doi:10.1016/j.biomaterials.2020.120621

Cited by 73 publications

(59 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to CAT, many metal‐based nanoenzymes including Pt (Equation (1)), [ 99,134–135 ] Mn (Equation (2)), [ 111,136–137 ] prussian blue (PB) (Equation (1)), [ 103,138–139 ] and Fe (Equations (3)–(7)) [ 105,108–109,110–141 ] based nanozymes possess CAT‐like catalytic capabilities for tumor reoxygenation. Some of these mechanisms are written below (Equations 1–7)

2 {normalH}_{2} {normalO}_{2} \overset{Pt or PB}{\to} 2 {normalH}_{2} O + {normalO}_{2}

{MnO}_{2} + {normalH}_{2} {normalO}_{2} + 2 {normalH}^{+} \to {Mn}^{2 +} + {normalO}_{2} + 2 {normalH}_{2} O

{Fe}^{2 +} + {normalH}_{2} {normalO}_{2} \to {Fe}^{3 +} +^{•} OH + {OH}^{-}

{Fe}^{3 +} + {normalH}_{2} {normalO}_{2} \to {Fe}^{2 +} + {HO}_{2}^{•} + {normalH}^{+}

{Fe}^{3 +} + {HO}_{2}

…”

Section: In Situ O2 Generationmentioning

confidence: 99%

Conquering the Hypoxia Limitation for Photodynamic Therapy

et al. 2021

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has aroused great research interest in recent years owing to its high spatiotemporal selectivity, minimal invasiveness, and low systemic toxicity. However, due to the hypoxic nature characteristic of many solid tumors, PDT is frequently limited in therapeutic effect. Moreover, the consumption of O2 during PDT may further aggravate the tumor hypoxic condition, which promotes tumor proliferation, metastasis, and invasion resulting in poor prognosis of treatment. Therefore, numerous efforts have been made to increase the O2 content in tumor with the goal of enhancing PDT efficacy. Herein, these strategies developed in past decade are comprehensively reviewed to alleviate tumor hypoxia, including 1) delivering exogenous O2 to tumor directly, 2) generating O2 in situ, 3) reducing tumor cellular O2 consumption by inhibiting respiration, 4) regulating the TME, (e.g., normalizing tumor vasculature or disrupting tumor extracellular matrix), and 5) inhibiting the hypoxia‐inducible factor 1 (HIF‐1) signaling pathway to relieve tumor hypoxia. Additionally, the O2‐independent Type‐I PDT is also discussed as an alternative strategy. By reviewing recent progress, it is hoped that this review will provide innovative perspectives in new nanomaterials designed to combat hypoxia and avoid the associated limitation of PDT.

show abstract

2 {normalH}_{2} {normalO}_{2} \overset{Pt or PB}{\to} 2 {normalH}_{2} O + {normalO}_{2}

{MnO}_{2} + {normalH}_{2} {normalO}_{2} + 2 {normalH}^{+} \to {Mn}^{2 +} + {normalO}_{2} + 2 {normalH}_{2} O

{Fe}^{2 +} + {normalH}_{2} {normalO}_{2} \to {Fe}^{3 +} +^{•} OH + {OH}^{-}

{Fe}^{3 +} + {normalH}_{2} {normalO}_{2} \to {Fe}^{2 +} + {HO}_{2}^{•} + {normalH}^{+}

{Fe}^{3 +} + {HO}_{2}

…”

Section: In Situ O2 Generationmentioning

confidence: 99%

Conquering the Hypoxia Limitation for Photodynamic Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In recent years, engineered exosomes have attracted growing research attention as drug delivery carriers for cancer treatment. This is partly because of their distinctive property of organotropism, which plays a crucial role in organ distribution following systemic administration [ 118 , 119 ]. Nie et al designed lung-specific exosomes (231-Exo) for miRNA-126 delivery into lung cancer.…”

Section: Clinical Applicationsmentioning

confidence: 99%

The role of exosomes in lung cancer metastasis and clinical applications: an updated review

et al. 2021

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-associated deaths accounting for 24% of all cancer deaths. As a crucial phase of tumor progression, lung cancer metastasis is linked to over 70% of these mortalities. In recent years, exosomes have received increasing research attention in their role in the induction of carcinogenesis and metastasis in the lung. In this review, recent studies on the contribution of exosomes to lung cancer metastasis are discussed, particularly highlighting the role of lung tumor-derived exosomes in immune system evasion, epithelial-mesenchymal transition, and angiogenesis, and their involvement at both the pre-metastatic and metastatic phases. The clinical application of exosomes as therapeutic drug carriers, their role in antitumor drug resistance, and their utility as predictive biomarkers in diagnosis and prognosis are also presented. The metastatic activity, a complex multistep process of cancer cell invasion, survival in blood vessels, attachment and subsequent colonization of the host's organs, is integrated with exosomal effects. Exosomes act as functional mediating factors in cell–cell communication, influencing various steps of the metastatic cascade. To this end, lung cancer cell-derived exosomes enhance cell proliferation, angiogenesis, and metastasis, regulate drug resistance, and antitumor immune activities during lung carcinogenesis, and are currently being explored as an important component in liquid biopsy assessment for diagnosing lung cancer. These nano-sized extracellular vesicles are also being explored as delivery vehicles for therapeutic molecules owing to their unique properties of biocompatibility, circulatory stability, decreased toxicity, and tumor specificity. The current knowledge of the role of exosomes highlights an array of exosome-dependent pathways and cargoes that are ripe for exploiting therapeutic targets to treat lung cancer metastasis, and for predictive value assessment in diagnosis, prognosis, and anti-tumor drug resistance.

show abstract

“…Under NIR irradiation, this system relieved tumor hypoxia and boosted PDT efficiency both in vitro and in vivo. The recent progress on the photosynthetic microorganism-enhanced PDT also includes the combination of microorganism and perfluorocarbons for oxygen production and collection [ 101 ], and improvement of biocompatibility via biomineralization [ 102 ].…”

Section: Strategies For Modulating Tumor Hypoxia In Pdtmentioning

confidence: 99%

Recent Advances in Strategies for Addressing Hypoxia in Tumor Photodynamic Therapy

Liang

Luo

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a treatment modality that uses light to target tumors and minimize damage to normal tissues. It offers advantages including high spatiotemporal selectivity, low side effects, and maximal preservation of tissue functions. However, the PDT efficiency is severely impeded by the hypoxic feature of tumors. Moreover, hypoxia may promote tumor metastasis and tumor resistance to multiple therapies. Therefore, addressing tumor hypoxia to improve PDT efficacy has been the focus of antitumor treatment, and research on this theme is continuously emerging. In this review, we summarize state-of-the-art advances in strategies for overcoming hypoxia in tumor PDTs, categorizing them into oxygen-independent phototherapy, oxygen-economizing PDT, and oxygen-supplementing PDT. Moreover, we highlight strategies possessing intriguing advantages such as exceedingly high PDT efficiency and high novelty, analyze the strengths and shortcomings of different methods, and envision the opportunities and challenges for future research.

show abstract

Light-controlled oxygen production and collection for sustainable photodynamic therapy in tumor hypoxia

Cited by 73 publications

References 66 publications

Conquering the Hypoxia Limitation for Photodynamic Therapy

Conquering the Hypoxia Limitation for Photodynamic Therapy

The role of exosomes in lung cancer metastasis and clinical applications: an updated review

Recent Advances in Strategies for Addressing Hypoxia in Tumor Photodynamic Therapy

Contact Info

Product

Resources

About